Akebia Therapeutics (AKBA) Accumulated Expenses (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Accumulated Expenses of $125.1 million for Q1 2026, up 75.31% year-over-year from $71.3 million in Q1 2025, and up 2.75% quarter-over-quarter from $121.7 million in Q4 2025.
Akebia Therapeutics (AKBA) Accumulated Expenses (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Accumulated Expenses for 14 consecutive years, with $125.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses rose 75.31% year-over-year to $125.1 million; the TTM figure through Mar 2026 stood at $125.1 million (up 75.31% YoY), while the FY2025 annual figure was $121.7 million, up 91.8% from the prior year.
- Accumulated Expenses advanced to $125.1 million in Q1 2026 per AKBA's latest filing, from $121.7 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $125.1 million in Q1 2026 and bottomed at $51.1 million in Q1 2023.
- Historically, Accumulated Expenses has averaged $79.7 million across 5 years, with a median of $71.3 million in 2025.
- Annual changes were most pronounced in 2023 — Accumulated Expenses sank 55.29% — and 2025, when it surged 103.81%.
- Akebia Therapeutics' Accumulated Expenses stood at $75.8 million in 2022, then retreated by 10.61% to $67.7 million in 2023, then slipped by 6.31% to $63.5 million in 2024, then jumped by 91.8% to $121.7 million in 2025, then climbed by 2.75% to $125.1 million in 2026.
- Business Quant data shows AKBA's Accumulated Expenses at $125.1 million in Q1 2026, $121.7 million in Q4 2025, and $106.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Akebia Therapeutics | 244.72 Mn | 89.17 Mn | 38.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 109.80 Mn |
| Mar 31, 2026 | 125.06 Mn |
| Dec 31, 2025 | 121.72 Mn |
| Sep 30, 2025 | 106.42 Mn |
| Jun 30, 2025 | 91.62 Mn |
| Mar 31, 2025 | 71.34 Mn |
| Dec 31, 2024 | 63.46 Mn |
| Sep 30, 2024 | 52.22 Mn |
| Jun 30, 2024 | 53.90 Mn |
| Mar 31, 2024 | 53.91 Mn |
| Dec 31, 2023 | 67.74 Mn |
| Sep 30, 2023 | 62.66 Mn |
| Jun 30, 2023 | 56.41 Mn |
| Mar 31, 2023 | 51.08 Mn |
| Dec 31, 2022 | 75.78 Mn |
| Sep 30, 2022 | 92.53 Mn |
| Jun 30, 2022 | 95.01 Mn |
| Mar 31, 2022 | 114.24 Mn |
| Dec 31, 2021 | 109.01 Mn |
| Sep 30, 2021 | 144.70 Mn |